The stock plummeted approximately 22% to reach 46 cents per share. In light of these circumstances, Eight Capital analyst Ty Collin revised his price target for Canopy Growth, setting it at $0 instead of C$1.75 ($1.32) per share. Collin also reiterated a sell rating for the company, stating that it is no longer appropriate to consider Canopy Growth as a viable business.
Legal on paper, restricted in practice. Inside Germany’s cannabis system, where cultivation is allowed but…
The idea may sound strange: a tobacco plant producing compounds like psilocybin or DMT. Sounds…
The term “addiction” gets thrown around quite freely in everyday language—this is nothing new. Who…
Three days before the Trump administration moved medical marijuana to Schedule III, a new YouGov…
On April 23, 2026, the Trump administration officially moved FDA-approved marijuana products and marijuana products…
Here we are in 2026, and a conflict that was supposed to wrap up in…